202 related articles for article (PubMed ID: 17317380)
1. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
Gotto AM
Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
[TBL] [Abstract][Full Text] [Related]
2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
3. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
4. [Inflammation and C-reactive protein in cardiovascular disease].
Munk PS; Larsen AI
Tidsskr Nor Laegeforen; 2009 Jun; 129(12):1221-4. PubMed ID: 19521445
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
Libby P; Ridker PM
Am J Med; 2004 Mar; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
[TBL] [Abstract][Full Text] [Related]
6. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
Ridker PM; MacFadyen J; Libby P; Glynn RJ
Am J Cardiol; 2010 Jul; 106(2):204-9. PubMed ID: 20599004
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein: a new risk assessment tool for cardiovascular disease.
Clearfield MB
J Am Osteopath Assoc; 2005 Sep; 105(9):409-16. PubMed ID: 16239491
[TBL] [Abstract][Full Text] [Related]
8. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
Ridker PM
Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
[TBL] [Abstract][Full Text] [Related]
9. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
Windgassen EB; Funtowicz L; Lunsford TN; Harris LA; Mulvagh SL
Postgrad Med; 2011 Jan; 123(1):114-9. PubMed ID: 21293091
[TBL] [Abstract][Full Text] [Related]
11. From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey.
Spatz ES; Canavan ME; Desai MM
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):41-8. PubMed ID: 20031811
[TBL] [Abstract][Full Text] [Related]
12. [C-reactive protein in cardiovascular risk evaluation].
Fabijanić D; Banić M; Kardum D
Lijec Vjesn; 2006; 128(5-6):167-74. PubMed ID: 16910418
[TBL] [Abstract][Full Text] [Related]
13. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein: a novel marker of cardiovascular risk.
Shah SH; Newby LK
Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
Ridker PM
J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
[TBL] [Abstract][Full Text] [Related]
16. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Koenig W
Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
[TBL] [Abstract][Full Text] [Related]
17. Markers of inflammation and cardiovascular disease: clinical applications of C-reactive protein determination.
Martínez VB; González-Juanatey JR
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():3-7. PubMed ID: 20000881
[TBL] [Abstract][Full Text] [Related]
18. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Li JJ; Fang CH
Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
[TBL] [Abstract][Full Text] [Related]
20. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein.
Koenig W
Int J Cardiol; 2005 Feb; 98(2):199-206. PubMed ID: 15686768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
